There has been a gradual increase in the use of evidence-based treatments and consequently a reduction in adverse cardiovascular outcomes over the past 20 years in patients with non-ST-elevation myocardial infarction (NSTEMI) in Sweden, according to results of the SWEDEHEART trial presented Nov. 14 at AHA 2017 in Anaheim, CA.

Karolina Szummer, MD, PhD, et al., looked at 205,693 NSTEMI cases in the SWEDEHEART Registry between 1994 and 2014.

Results showed that the standardized one-year mortality ratio in NSTEMI compared to the control population decreased from 5.53 in 1995/1996 to 3.03 in 2013/2014. Further, there was an improvement in long-term survival and reductions in the risk of new ischemic events and heart failure.

The researchers explain that "improvements in outcomes [are] mainly explained by implementation of early coronary interventions and … evidence-based medical treatments." They add that "continued and increased uptake of currently guideline recommended treatments can be expected to further improve outcomes."

Keywords: AHA17, AHA Annual Scientific Sessions, Registries, Treatment Outcome

< Back to Listings